RE: A Phase II Study of the PARP Inhibitor, Iniparib (BSI-201), in Combination with Chemotherapy to Treat Triple Negative Breast Cancer Brain Metastasis (NA_00036553, SKCCC J1081, TBCRC 018)

Dear Fellow Physician,

It is our pleasure to send a brief update of our phase II research study evaluating the efficacy of Iniparib (BSI-201, Sanofi-Aventis/BiPAR Sciences), plus irinotecan chemotherapy to treat women with progressive triple negative breast cancer brain metastases.

Below are some high points:

- Eligibility includes two groups: (1) patients with progressive brain metastases after radiation therapy, or (2) patients who are radiation therapy-naive and asymptomatic.
- Treatment includes irinotecan on days 1 and 8 of a 21 day cycle, with iniparib on days 1, 4, 8 and 11. All study-based therapy will be administered intravenously.
- Monitoring for intracranial and extracranial response will occur every 9 weeks with a brain MRI and a CT of chest/abdomen and pelvis.

This trial is being open through the Translational Breast Cancer Research Consortium and includes several sites across the country. Please see more information here:


We would welcome referrals of your patients with triple negative breast cancer brain metastases. For more information or to discuss eligibility questions, please email HopkinsBreastTrials@jhmi.edu.

Sincerely,

Vered Stearns, M.D.

Principal Investigator: Vered Stearns, M.D.
Protocol Number: NA_00036553